Merck to Acquire Terns Pharma for $6 Billion to Bolster Cancer Pipeline
Pharmaceutical giant Merck & Co. announced Wednesday it is nearing a $6 billion all-cash acquisition of U.S. Biotech firm Terns Pharmaceuticals. The deal aims to strengthen Merck’s oncology portfolio as it prepares for the patent expiration of its blockbuster drug, Keytruda, in 2028.
Strategic Move Ahead of Keytruda Patent Expiration
The acquisition of Terns Pharma is part of a broader strategy by Merck to diversify its drug pipeline and reduce its reliance on Keytruda, which currently generates a significant portion of the company’s revenue. The looming loss of exclusivity for Keytruda in 2028 is a major concern for the company, prompting it to actively seek latest growth opportunities.
Terns Pharma’s Pipeline and Focus
Terns Pharmaceuticals specializes in the development of compact molecule drugs targeting cancer. While specific details of Terns’ pipeline were not immediately available, the acquisition is expected to provide Merck with promising new candidates to advance through clinical trials. The deal is anticipated to boost Merck’s cancer drug portfolio and provide a buffer against the revenue decline expected after Keytruda’s patent expires.
Recent Acquisitions Reflect Merck’s Growth Strategy
This acquisition marks the third multibillion-dollar deal for Merck in the past year, demonstrating the company’s commitment to expanding its pharmaceutical offerings. These strategic investments are designed to position Merck for continued growth and innovation in the competitive pharmaceutical landscape.
Market Reaction
Following the announcement, Terns shares experienced a 5.3% increase in premarket trading, while Merck’s stock remained relatively stable.
This is a developing story and will be updated as more information becomes available.
Keep reading